Global Urticaria Drug Market Size, Share and Trends Analysis Report, By Disease Type (Acute Urticaria and Chronic Urticaria), By Drug Type (Antihistamines, H2-blockers, Monoclonal Antibodies, Antidepressants, and Others), By Route of Administration (Oral, Topical, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast (2022-2028)

The global urticaria drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Urticaria also known as hives, occurs when the body reacts to an allergen and releases histamine and other chemicals from under the surface of the skin. The major factor expected to drive the market is the rising incidences of urticaria, growing drug approvals for urticaria treatment, easy availability of generic medication, and growing awareness regarding hypersensitivity and allergies. Furthermore, the development of novel targeted therapies, such as omalizumab for the management of chronic urticarial, and increasing clinical access to diverse geographical will further drive the urticaria drug market during the forecast period. Due to growing cases of urticaria it creates an opportunity for the pharma companies to introduce novel therapy and promising pipeline drugs along with advances in the treatment rate will further boost the growth of the market in the forecast period.

Some major players in the market include Johnson and Johnson Services Inc., Novartis International AG, and Amneal Pharmaceuticals, Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in October 2019, JDP Therapeutics Inc. announced that the company received approval from the United States Food and Drug Administration (USFDA) for cetirizine injection (quzyttir) for the treatment of acute urticaria. Furthermore, in September 2018, Novartis AG states that the company obtained approval from the US Food and Drug Administration (USFDA) for Xolair (omalizumab) prefilled syringe formulation for chronic idiopathic urticaria.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Disease Type
  • By Drug Type
  • By Route of Administration
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

• Competitive Landscape- Johnson and Johnson Services Inc., Novartis International AG, and Amneal Pharmaceuticals, Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Urticaria Drug Market Report by Segment

By Disease Type

• Acute Urticaria
• Chronic Urticaria

By Drug Type

• Antihistamines
• H2-blockers
• Monoclonal Antibodies
• Antidepressants
• Others

By Route of Administration

• Oral
• Topical
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Urticaria Drug Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa